NCT04472286

Brief Summary

This project will examine habitual physical activity, bone health, and insulin resistance in pediatric acute lymphocytic leukemia (ALL) and lymphoma cancer survivors at two time points: baseline and 6 months. At the two study timepoints, all study participants will be asked to wear an accelerometer, receive a DXA scan of the lumbar spine and hip, and have blood drawn for analysis. Study participants will be given a gift card stipend for each study visit attended. Study visits will coincide with regular office visits to Children's Hospital Oncology Clinic and the Children's Hospital Survivorship Clinics whenever possible. The potential mechanism by which physical activity mediates bone changes will be explored by concurrently measuring changes in lean/fat mass and metabolic status. This pilot study will provide data to inform the design of a randomized controlled trial to test the effect of a physical activity intervention on bone health in PCS.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Nov 2020

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 10, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

July 15, 2020

Completed
4 months until next milestone

Study Start

First participant enrolled

November 1, 2020

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 30, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 30, 2024

Completed
Last Updated

August 30, 2024

Status Verified

August 1, 2024

Enrollment Period

3.6 years

First QC Date

July 10, 2020

Last Update Submit

August 28, 2024

Conditions

Outcome Measures

Primary Outcomes (3)

  • Bone Mineral Density (g/cm2)

    z-score of lumbar Spine bone density- DXA scan

    6 months

  • Hip structural analysis

    DXA scan

    6 months

  • Physical Activity Level

    Physical Activity as measured by accelerometry

    6 months

Secondary Outcomes (4)

  • Lipid panel

    6 months

  • Homeostatic Model Assessment for Insulin Resistance

    6 months

  • Hemoglobin A1c

    6 months

  • Vitamin D

    6 months

Study Arms (1)

Pediatric Cancer Survivors

Children and adolescents who have completed treatment of for acute lymphoblastic leukemia (ALL) and lymphoma.

Eligibility Criteria

Age5 Years - 18 Years
Sexall
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Pediatric cancer survivors who are in the first year after treatment completion

You may qualify if:

  • Children between the ages of 5-18
  • Diagnosis of ALL or Lymphoma
  • Between 1-13 months post-cancer treatment

You may not qualify if:

  • Children younger than 5 years old or 19 or older
  • Children without a diagnosis of ALL or lymphoma
  • Children receiving ongoing cancer treatment
  • Children with Down syndrome (identified as a precancerous condition affecting BMD)
  • Children with a prior history of bisphosphonate use or other medication directed at increasing bone density

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States

Location

MeSH Terms

Conditions

Precursor Cell Lymphoblastic Leukemia-LymphomaBone Diseases, MetabolicMetabolic SyndromeLymphomaLeukemiaLeukemia, LymphoidOsteoporosis

Condition Hierarchy (Ancestors)

Neoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic DiseasesLymphoproliferative DisordersLymphatic DiseasesImmunoproliferative DisordersImmune System DiseasesBone DiseasesMusculoskeletal DiseasesMetabolic DiseasesNutritional and Metabolic DiseasesInsulin ResistanceHyperinsulinismGlucose Metabolism Disorders

Study Officials

  • Laura D Bilek, PhD

    University of Nebraska

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 10, 2020

First Posted

July 15, 2020

Study Start

November 1, 2020

Primary Completion

May 30, 2024

Study Completion

May 30, 2024

Last Updated

August 30, 2024

Record last verified: 2024-08

Data Sharing

IPD Sharing
Will not share

Locations